6 biotech companies leading the GLP-1 agonist obesity field
This issue of our newsletter is supported by Wacker Biotech.
As we probably all know by now, obesity drugs are heavily in demand at the moment, particularly GLP-1 agonists.
Novo Nordisk’s Wegovy has had a major stake in the market since its approval in 2021 and brought in 9.4 billion Danish kroner ($1.40 billion) in the first quarter of this year.
Furthermore, Lilly’s Zepbound was greenlit late last year and made over a billion in sales this quarter.
The global market for obesity drugs is now expected to hit $105 billion in 2030, more than $30 billion higher than a previous forecast owing to surging demands.
And the demand is likely to be met, as the obesity field is brimming with candidates.
This week, we take a look at which biotech companies are currently at the forefront of the GLP-1 field.
To find out more, read the full article: “Six biotech companies that could revolutionize obesity treatments”
A MESSAGE FROM OUR SPONSOR WACKER BIOTECH
Engage the experts for novel pDNA, mRNA, and LNP formulations and manufacturing
Wacker Biotech is your CDMO partner for advanced therapies, offering the production of pDNA, mRNA, LNPs and fill and finish. We are a highly engaged team with decades of CDMO experience you can trust. Global facilities with integrated pDNA, mRNA and LNP capabilities support our robust nucleic acid services.
🔥 More noteworthy articles from this week:
While surgery is a common treatment for early-stage endometrial cancer, it is not the case for advanced forms of the disease, which is why new treatment approvals are needed to help patients suffering from this condition. In this article, we look at the latest therapies that have been approved and those currently in development for the treatment of endometrial cancer.
The companies Borealis Biosciences, Outpace Bio, and Halda Therapeutics bagged the biggest private biotech investments in August 2024. And, around the world, oncology players attracted the biggest funding rounds overall, followed by central nervous system (CNS), immunology, rare disease, and renal disease companies.
The recent decision by the U.S. FDA to reject Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy as a treatment for PTSD could mark a significant moment for the future of psychedelic drug development. The review by an FDA advisory committee raised concerns about the efficacy and safety of MDMA therapy, citing issues like “functional unblinding” and risks associated with its psychoactive effects.
The therapeutic field of long non-coding (lnc) RNAs has flown under the radar for quite some time now since they emerged as targets belonging to the dark genome to treat various diseases. But recent deals have zoned in on drugs that target lncRNAs and major moves are currently being made on the R&D front.
Iovance recently submitted a marketing authorization application to the European Medicines Agency for lifileucel, a tumor infiltrating lymphocyte (TIL) cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma. This week, we have a conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline.
The application for investigational new drug and Clinical Trial Application is a key step in initiating clinical trials / first-in-human (FIH) trials for a drug candidate. Furthermore, its approval can help companies secure additional funding and facilitate pipeline generation. However, pre-clinical toxicology studies can present a bottleneck for companies on the path to FIH. Accelerating their timelines through rapid toxicology material delivery can be an effective way to reduce a drug candidate’s time to enter the clinic.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.